Genomic analysis of Barrett's esophagus after ablative therapy: Persistence of genetic alterations at tumor suppressor loci

International Journal of Cancer

Volumn 118, Issue 1, 2006, Pages 155-160

  Hage, Mariska ^a   Siersema, Peter D ^a   Vissers, Kees J ^a   Dinjens, Winand N M ^a   Steyerberg, Ewout W ^a   Haringsma, Jelle ^a   Kuipers, Ernst J ^a   Van Dekken, Herman ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Allelic loss; Argon plasma coagulation; Dysplasia; Intestinal metaplasia; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; PROTEIN P53; SMAD4 PROTEIN;

ADULT; AGED; ALLELISM; ARGON PLASMA COAGULATION; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER SUSCEPTIBILITY; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 5Q; CHROMOSOME 9P; CLINICAL ARTICLE; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; GENETIC LINE; GENOMICS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; INTESTINE METAPLASIA; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENT DISEASE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; BARRETT ESOPHAGUS; CELL TRANSFORMATION, NEOPLASTIC; ESOPHAGEAL NEOPLASMS; FEMALE; GENES, P53; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; POLYMORPHISM, GENETIC; RECURRENCE; TREATMENT OUTCOME;

EID: 27944467868     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21302     Document Type: Article

References (45)

1. Winters C Jr, Spurling TJ, Chobanian SJ, Curtis DJ, Esposito RL, Hacker JF 3rd, Johnson DA, Cruess DF, Cotelingam JD, Gurney MS. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology 1987;92:118-24.
2. Phillips RW, Wong RK. Barrett's esophagus. Natural history, incidence, etiology, and complications. Gastroenterol Clin N Am 1991;20:791-816.
3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999;340:825-31.
4. Hage M, Siersema PD, van Dekken H, Steyerberg E, Dees J, Kuipers EJ. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years. Scan J Gastroenterol 2004;39:1175-9.
5. Haggitt RC. Barrett's esophagus, dysplasia, and adenocarcinoma. Hum Pathol 1994;25:982-93.
6. Hameeteman W, Tytgat GN, Houthoff HJ, van den Tweel JG. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
7. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-6.
8. Van Laethem J-L, Cremer M, Peny MO, Delhaye M, Devière J. Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results. Gut 1998;43:747-51.
9. Mork H, Barth T, Kreipe HH, Kraus M, Al-Taie O, Jacob F, Scheurlen M. Reconstitution of squamous epithelium in Barrett's esophagus with endoscopic argon plasma coagulation: a prospective study. Scand J Gastroenterol 1998;33:1130-4.
10. Pereira-Lima JC, Busnello JV, Saul C, Toneloto EB, Lopes CV, Rynkowsli CB, Blaya C. High power setting argon plasma coagulation for the eradication of Barrett's esophagus. Am J Gastroenterol 2000;95:1661-8.
11. Morris CD, Byrne JP, Armstrong GRA, Attwood SE. Prevention of the neoplastic progression of Barrett's oesophagus by endoscopic argon beam plasma ablation. Br J Surg 2001;88:1357-62.
12. Basu KK, Pick B, Bale R, West KP, de Caestecker JS. Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett's esopahgus: factors determining persistence and recurrence of Barrett's esophagus. Gut 2002;51:776-80.
13. Barr H, Shepherd NA, Dix A, Roberts DJH, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett's) esophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996;348:584-5.
14. Gossner L, Stolte M, Sroka R, Rick K, May A, Hahn EG, Ell C. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998;114:448-55.
15. Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Marcus SL, Stoddard CJ, Johnson AG, Reed MWR. Photodynamic therapy for dysplastic Barrett's esophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 2000;47:612-7.
16. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58:183-8.
17. Hage M, Siersema PD, van Dekken H, Steyerberg EW, Haringsma J, van de Vrie W, Grool TE, van Veen RLP, Sterenborg HJCM, Kuipers EJ. 5-aminolevulenic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's esophagus: a randomized trial. Gut 2004;53:785-90.
18. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ, Russell SE. Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 1995;55:3406-11.
19. Barrett MT, Sanchez CA, Galipeau PC, Neshat K, Emond M, Reid BJ. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-73.
20. Gonzalez MV, Artimez ML, Rodrigo L, Lopez-Larrea C, Menedez MJ, Alvarez V, Perez R, Fresno MF, Perez MJ, Sampedro A, Goto EI. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia and adenocarcinoma. J Clin Pathol 1997;50:212-7.
21. 1NK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res 1997;57:2619-22.
22. Klump B, Hsieh CJ, Holzmann K, Gregor M, Forschen R. Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology 1998;115:1381-6.
23. Petty EM, Kalikin LM, Orringer MB, Beer DG. Distal chromosome 17q loss in Barrett's esophageal and gastric cardia adenocarcinomas: implications for tumorigenesis. Mol Carcinog 1998;22:222-8.
24. Dolan K, Garde J, Gosney J, Sissons M, Wright T, Kingsnorth AN, Walker SJ, Sutton R, Meltzer SJ, Field JK. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br J Cancer 1998;78:950-7.
25. Bian YS, Osterheld MC, Fontolliet C, Bosman FT, Benhattar J. P16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 2002;122:1113-21.
26. Walch AK, Zitzelsberger HF, Bruch J, Keller G, Angermeier D, Aubele MM, Mueller J, Stein H, Braselmann H, Siewert JR, Höfler H, Werner M. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia- carcinoma sequence. Am J Pathol 2000;156:555-66.
27. Riegman PHJ, Vissers KJ, Alers CJ, Geelen E, Hop WCJ, Tilanus HW, van Dekken H. Genomic alterations in malignant transformation of Barrett's esophagus. Cancer Res 2001;61:3164-70.
28. Blount PL, Galipeau PC, Sanchez CA, Neshat K, Levine DS, Yin J, Suzuki H, Abraham JM, Meltzer SJ, Reid BJ. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994;54:2292-5.
29. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 1996;93:7081-4.
30. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, Blount PL, Rabinovitch PS. Predictors of progression in Barrett's Esophagus II: Baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
31. Blount PL, Meltzer SJ, Yin J, Huang Y, Krasna MJ, Reid BJ. Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci USA 1993;90:3221-5.
32. Zhuang Z, Vortmeyer AO, Mark EJ, Odze R, Emmert-Buck MR, Merino MJ, Moon H, Liotta LA, Duray PH. Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. Cancer Res 1996;56:1961-4.
33. Wu TT, Watanabe T, Heitmiller R, Zahurak M, Forastiere AA, Hamilton SR. Genetic alterations in Barrett's esophagus and adenocarcinomas of the esophagus and the esophagogastric junction. Am J Pathol 1998;153:287-94.
34. Dolan K, Garde J, Walker SJ, Sutton R, Gosney J, Field JK. LOH at the sites of the DCC, APC, and TP53 tumor suppressor genes occurs in Barrett's metaplasia and dysplasia adjacent to adenocarcinoma of the esophagus. Hum Pathol 1999;30:1508-14.
35. Riegman PHJ, Burgart LJ, Wang KK, Wink-Godschalk JCJ, Dinjens WNM, Siersema PD, Tilanus HW, van Dekken H. Allelic imbalance of 7q32.3-q36.1 during tumorigenesis in Barrett's esophagus. Cancer Res 2002;62:1531-3.
36. Spechler SJ. Clinical practice. Barrett's Esophagus. N Engl J Med 2002;346:836-42.
37. INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
38. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitc PS, Reid BJ. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
39. Galipeau PC, Prevo PL, Sanchez CA, Longton GM, Reid BJ. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999;99:2087-95.
40. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Blount PL, Reid BJ. The combination of genetic instability and clonal expansion predict progression to esophageal adenocarcinoma. Cancer Res 2004;64:7629-33.
41. Sharma P. An update on strategies for eradication of Barrett's mucosa. Am J Med 2001;11(Suppl 8A):147S-152S.
42. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's esophagus. Gut 2000;46:574-7.
43. Shand A, Dallai H, Palmer K, Ghosh S, MacIntyre M. Adenocarcinoma arising in columnar lined esophagus following treatment with argon plasma coagulation. Gut 2001;48:580-81.
44. Krishnadath KK, Wang KK, Taniguchi K, Sebo TJ, Buttar NS, Anderson MA, Lutzke LS, Liu W. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy. Gastroenterology 2000;119:624-30.
45. Hage M, Siersema PD, Vissers KJ, Steyerberg EW, Haringsma J, Kuipers EJ, van Dekken H. Molecular evaluation of ablative therapy of Barrett's esophagus. J Pathol 2005;205:57-64.